Controversies in the Management of Early-Stage Hodgkin Lymphoma
Search for other papers by Ranjana H. Advani in
Current site
Google Scholar
PubMed
Early-stage Hodgkin lymphoma is a highly curable malignancy, but controversies surrounding treatment recommendations persist due to the sheer number of treatment choices available, as well as the effort to balance risk versus benefit for each individual patient. The gold standard for treatment has evolved over the years. Currently, in the PET era, fine-tuning therapy approaches is largely focused on avoiding giving too much therapy to patients with a negative interim PET and too little therapy to those with a positive interim PET. Careful patient selection for therapy has become increasingly important, as patient risk factors for early-stage disease are variably defined by German Hodgkin Study Group, EORTC, and NCCN criteria.
Disclosures: Dr. Advani has disclosed that she has received consulting fees from ADC Therapeutics, Celgene Corporation, Genentech, Inc./Roche Laboratories, Inc., Gilead Sciences, Inc., Portola Pharmaceuticals, Inc., Sanofi-Aventis U.S., Seattle Genetics, Inc., Kura Oncology, Inc, Karyopharm, and Takeda Pharmaceuticals North America, Inc.; and received institutional grant/research support from Forty Seven, Inc., Genentech, Inc./Roche Laboratories, Inc., Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.
© 2019-2024 National Comprehensive Cancer Network